No changes of cholesterol levels with a commercially available glucosamine product in patients treated with lipid lowering drugs: a controlled, randomised, open cross-over trial
| Autor: | Lennart Andrén, Åke Andreasson, Robert Eggertsen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Blood Glucose
Male Simvastatin Atorvastatin Osteoarthritis Pharmacology law.invention chemistry.chemical_compound Randomized controlled trial law Glucosamine Medicine Humans Pharmacology (medical) In patient Drug Interactions Pyrroles cardiovascular diseases Triglycerides Aged Cross-Over Studies business.industry Cholesterol Anticholesteremic Agents nutritional and metabolic diseases Middle Aged medicine.disease Crossover study chemistry Heptanoic Acids lipids (amino acids peptides and proteins) Female business medicine.drug Research Article |
| Zdroj: | BMC Pharmacology & Toxicology |
| ISSN: | 2050-6511 |
| Popis: | Background The widespread use of natural health products is also a problem, as they could interact with prescribed drugs in patients. One commonly used product is glucosamine for osteoarthritis and some reports have found increased values of cholesterol and other lipids in patients treated with simvastatin for hypercholesterolemia. The aim of this trial was to investigate the effects of glucosamine on s-cholesterol levels (total s-cholesterol, s-HDL, s-LDL) in primary care patients on treatment with simvastatin or atorvastatin. Methods Controlled, randomized, open, crossover pharmacodynamic study in two primary health care centres. Patients were treated with Artrox® (glucosamine) 625 mg twice daily and control (a commercially available multivitamin tablet Vitamineral®). The study started with a run-in period of four weeks followed by control or active treatment with randomization of sealed envelopes. Each treatment period was four weeks and the treatment with simvastatin or atorvastatin was unchanged during the study (12 weeks). 34 patients were treated with a stable dose of simvastatin (n=21) or atorvastatin (n=13) for at least three months. Assessments of total s-cholesterol, s-HDL, S-LDL and s-triglycerides were performed in the morning with the patients in a fasting condition. T-tests for paired samples were used for statistical analyses and a p-value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|